This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Bottomley, J. M Search for Related Content Social Bookmarking                         What's this?

Managing care of type 2 diabetes. Learnings from T2ARDIS*

GlaxoSmithKline Pharmaceuticals, Mundells, Welwyn Garden City, Hertfordshire

T2ARDIS Steering Committee and UK Centres

The T²ARDIS* survey reported total resource use in the NHS and Social Services for people with type 2 diabetes.

Patients and methods Cross-sectional postal survey data were acquired from a random sample of people diagnosed with type 2 diabetes from population-wide diabetes registers. Aggregated resource use, implications for healthcare management, and costs in the NHS and Social Services were considered. The data were compared to resource data in the general population to determine the impact of developing diabetic complications, particularly vascular disease. Implications for services were also considered.

Results At a population level, on average one in four patients reported microvascular complications, one in 10 macrovascular complications and one in 14 reported both. Compared to the general population, people with type 2 diabetes were admitted to hospital more often and stayed longer as in-patients. This trend was similar for out-patient care. Across the whole cohort, more than 40% of the NHS cost was due to in-patient care. Diabetic complications increased costs in the NHS and Social Services, costs of insulin products and other drugs. The average annual spend on oral antidiabetic drugs accounted for only 2% of NHS costs for diabetes.

Conclusion Most of the costs of care for the person with type 2 diabetes are borne by the NHS and the hospital sector. T²ARDIS* has probably under-estimated costs of the co-morbidity of type 2 diabetes. Complications significantly increase costs across all sectors. Evidence indicates that preventing the vascular complications of diabetes could avoid or delay hospitalisations and disability. Targeting resources should optimise the use of available services.

Key Words: Type 2 diabetes • vascular disease • economic survey • resource use • NHS costs • Social Services costs • patient and carer view • diabetic complications.

The British Journal of Diabetes & Vascular Disease, Vol. 1, No. 1, 68-72 (2001)
DOI: 10.1177/14746514010010011201


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				J C. Agwu Screening for type 2 diabetes mellitus in children and adolescents The British Journal of Diabetes & Vascular Disease, July 1, 2008; 8(4): 163 - 168. [Abstract] [PDF]

				J. Bottomley Economic costs of diabetes in the US in 2007 -- Implications for Europe The British Journal of Diabetes & Vascular Disease, March 1, 2008; 8(2): 96 - 100. [Abstract] [PDF]

				J. Bottomley, A. J Palmer, R. Williams, J. Dormandy, and M. Massi-Benedetti Review: PROactive 03: Pioglitazone, type 2 diabetes and reducing macrovascular events -- economic implications? The British Journal of Diabetes & Vascular Disease, March 1, 2006; 6(2): 63 - 70. [Abstract] [PDF]

				S. Jarvis Self-monitoring of blood glucose: is it worth it? The British Journal of Diabetes & Vascular Disease, September 1, 2005; 5(5): 245 - 246. [PDF]

				P. Stott Quality driven management of tablet-treated type 2 diabetes -- potential increases in GP practice prescribing costs The British Journal of Diabetes & Vascular Disease, January 1, 2003; 3(1): 64 - 68. [Abstract] [PDF]